Long-term Registry of Patients Treated With Loncastuximab Tesirine
NCT05160064 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2022-06-22
Summary
Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.
Conditions
- B-Cell Lymphomas
Sponsors & Collaborators
-
ADC Therapeutics S.A.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-30
- Primary Completion
- 2024-12-31
- Completion
- 2025-01-31
Countries
- United States
Study Locations
More Related Trials
-
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
NCT05600686 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
NCT05222438 ·Status: WITHDRAWN ·Phase: PHASE2
-
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
NCT05228249 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719 ·Status: RECRUITING ·Phase: PHASE2
-
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
NCT06788964 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
NCT03684694 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NCT03685344 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
NCT05144009 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT03589469 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
NCT04974996 ·Status: WITHDRAWN ·Phase: PHASE1
-
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
NCT05270057 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
NCT05660395 ·Status: RECRUITING ·Phase: PHASE1
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
NCT06919939 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide and R-CHOP in B-cell Lymphoma
NCT00901615 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125 ·Status: UNKNOWN
-
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04705454 ·Status: NO_LONGER_AVAILABLE
-
Acute Lymphoblastic Leukemia Registry at Asan Medical Center
NCT01761682 ·Status: TERMINATED
-
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
NCT01516580 ·Status: COMPLETED ·Phase: PHASE3
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Aggressive Localized Lymphoma
NCT00841945 ·Status: TERMINATED ·Phase: PHASE3
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156 ·Status: RECRUITING ·Phase: PHASE2
-
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
NCT06912529 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
NCT00169169 ·Status: TERMINATED ·Phase: PHASE3